AstraZeneca has rejected Pfizer's latest offer to buy AstraZeneca. Pfizer says its offer, which values AstraZeneca at £69 billion ($116 billion), is "final" and cannot be improved. "We have rejected...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.